There is relatively little published evidence indicating that GCS inhibition or silencing blocks tumour growth in vivo, but a stabilised antisense oligonucleotide targeting GCS reduces the growth of adriamycin-resistant cancer cells and greatly sensitizes these cells to doxorubicin in a xenograft model [206,207]. Here, UGCG is linked to cancer.